Real-world effectiveness of palbociclib + endocrine therapy in tumor histological subgroups of patients with HR+/HER2- Advanced Breast Cancer: Interim Results of the PERFORM study.

15. Januar 2026

R. Bartsch, M. Korell, G. Pfeiler, T. Gabrysiak, V. Petersen, M. Deryal, T.J. Fietz, J.C. Radosa, T. Decker, B. Schöttker, J. Knoblich, U. Rhein, N. Deuerling, M. Glasstetter, K. Gratzke, A. Wegenast, E. Glastetter, S. Sener, J. Dzieran, M.P. Lux.

Annals of Oncology, Volume 36, Supplement 2, 2025, Page S394, ISSN 0923-7534, https://doi.org/10.1016/j.annonc.2025.08.942

Poster